Clinical Features and Treatment of Systemic JIA in Children
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeUp to 18
SponsorSohag University
About this trial
This study aims to describe the clinical features, disease patterns, and different treatment modalities used in children with systemic juvenile idiopathic arthritis (sJIA). The study will include children younger than 18 years who meet the established classification criteria for sJIA. Clinical findings, laboratory investigations, disease activity, complications, and treatments received will be assessed. Participants will be followed prospectively to evaluate their clinical course and response to different therapeutic approaches. The study will help improve understanding of sJIA in children and provide information about the outcomes associated with different treatment modalities.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Children aged <18 years.
Children diagnosed with systemic juvenile idiopathic arthritis (sJIA) according to the 2019 PRINTO classification criteria.
Both newly diagnosed and previously diagnosed children with sJIA attending the study center.
Disqualifiers
Children with other rheumatic or autoimmune diseases.
Children with infectious, malignant, or other systemic diseases that may mimic sJIA.
Patients whose medical records have insufficient data for assessment.
Trial population
The study population will consist of children younger than 18 years of age diagnosed with systemic juvenile idiopathic arthritis (sJIA) according to the 2019 PRINTO classification criteria. Participants will be recruited from the pediatric rheumatology service and followed prospectively to assess their clinical course, disease activity, response to treatment, treatment-related outcomes, and disease complications.
Trial design
Design model
Other
Time perspective
Prospective
Treatments tested in this trial
Tocilizumab (Actemra®)
DrugTocilizumab used as part of routine clinical care for the management of systemic juvenile idiopathic arthritis. The treatment regimen, duration, and clinical response will be documented according to the treating physician's clinical practice.
Treatment groups
No treatment groups listed
Trial outcomes
Primary outcomes
1
Disease Activity in Children with Systemic Juvenile Idiopathic Arthritis
Disease activity will be assessed using the Juvenile Arthritis Disease Activity Score-10 (JADAS-10) at baseline and during follow-up after treatment initiation.
Time frame
At baseline and at 1, 3, 6, 9, and 12 months after treatment initiation.Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: